Apotex Recalls One Lot of Generic Ozempic Pens: What It Means for the Generic vs Brand Choice

What was recalled

On September 23, 2026, Apotex recalled one lot of its generic Ozempic pen. Health Canada says pens from the affected lot may show, and then deliver, a 0.25 mg or 0.5 mg dose in the dose window when a 1 mg dose is expected.

• Product: Apo-Semaglutide injection, 1 mg-dose pen (4 mg/pen), DIN 02568012, 1.34 mg/mL
• Affected lot: 7000636A
• Recall date: September 23, 2026 (Health Canada reference RA-82679, Type II, retail depth)
• Distribution: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario and Quebec

Check your pen

Find the lot number on the pen or its box. If it reads 7000636A, do not stop your medication on your own. Speak to your pharmacist or prescriber first. Questions about the recall go to Apotex, and any side effect can be reported to Health Canada.

What it changes for a generic vs brand comparison

A single lot recall is a manufacturing event, not a verdict on generic semaglutide. It does, however, add one practical question to our comparisons: which manufacturer's pen will your pharmacy actually dispense? Two generics are on the market today (Apotex and Dr. Reddy's), so it is worth asking.

Cost is still the main reason people choose generic. Brand-name programs generally cost more at maintenance doses, and we set out the difference in our generic semaglutide comparison. What this recall shows is that the cheaper option is not automatically the only option worth considering.